Zhixiang Jintai announced that the company has initiated phase III clinical trials of GR1802 injection in patients with chronic rhinosinusitis with nasal polyps. GR1802 injection is a self-developed recombinant humanized anti-IL-4Rα monoclonal antibody, which has obtained clinical trial approval notices for five indications. The main efficacy endpoint of the indication for chronic rhinosinusitis with nasal polyps has already reached phase II clinical trials, and phase III clinical trials have now been formally initiated.
智翔金泰：GR1802注射液启动III期临床试验
Zhixiang Jintai: GR1802 injection has initiated Phase III clinical trial.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.